Novo Nordisk drops 'Nordisk' as Eli Lilly pulls further ahead in obesity drugs
The Danish drugmaker is rebranding as Novo after a bruising stretch: its shares have lost around 20% over the past year, and Eli Lilly now holds 61% of the US obesity drug market to Novo's 39%. A fuller strategy update is due in London on September 21.
2 min read